[go: up one dir, main page]

CN108024959A - 用于治疗乳腺病症的经乳头方法和组合物 - Google Patents

用于治疗乳腺病症的经乳头方法和组合物 Download PDF

Info

Publication number
CN108024959A
CN108024959A CN201680052914.XA CN201680052914A CN108024959A CN 108024959 A CN108024959 A CN 108024959A CN 201680052914 A CN201680052914 A CN 201680052914A CN 108024959 A CN108024959 A CN 108024959A
Authority
CN
China
Prior art keywords
composition
breast
nipple
vitamin
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680052914.XA
Other languages
English (en)
Chinese (zh)
Inventor
史蒂文·C·夸伊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Atropic SA Genetics Corp
Atossa Therapeutics Inc
Original Assignee
Atropic SA Genetics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Atropic SA Genetics Corp filed Critical Atropic SA Genetics Corp
Publication of CN108024959A publication Critical patent/CN108024959A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0041—Mammary glands, e.g. breasts, udder; Intramammary administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Epoxy Compounds (AREA)
CN201680052914.XA 2015-07-14 2016-07-14 用于治疗乳腺病症的经乳头方法和组合物 Pending CN108024959A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562192505P 2015-07-14 2015-07-14
US62/192,505 2015-07-14
PCT/US2016/042202 WO2017011623A1 (en) 2015-07-14 2016-07-14 Transpapillary methods and compositions for treating breast disorders

Publications (1)

Publication Number Publication Date
CN108024959A true CN108024959A (zh) 2018-05-11

Family

ID=57757662

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680052914.XA Pending CN108024959A (zh) 2015-07-14 2016-07-14 用于治疗乳腺病症的经乳头方法和组合物

Country Status (7)

Country Link
US (1) US20180200206A1 (de)
EP (1) EP3322406A4 (de)
JP (1) JP2018520182A (de)
CN (1) CN108024959A (de)
AU (1) AU2016294526A1 (de)
CA (1) CA2992282A1 (de)
WO (1) WO2017011623A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10441654B2 (en) 2014-01-24 2019-10-15 Children's Hospital Of Eastern Ontario Research Institute Inc. SMC combination therapy for the treatment of cancer
US20180049999A1 (en) * 2015-04-14 2018-02-22 Atossa Genetics Inc. Compositions and methods of treatment of breast disorders and estrogen-related disorders
US11791043B2 (en) * 2017-09-06 2023-10-17 University Of Cincinnati Methods of prognosing early stage breast lesions
WO2019051416A1 (en) 2017-09-11 2019-03-14 Atossa Genetics Inc. METHODS FOR THE MANUFACTURE AND USE OF ENDOXIFEN
CN110221068B (zh) * 2018-03-02 2020-09-18 中国医学科学院基础医学研究所 检测Kyn含量的试剂的应用
MX2022000203A (es) 2019-07-03 2022-03-22 Atossa Therapeutics Inc Composiciones de liberacion sostenida de endoxifeno.

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040030248A1 (en) * 2002-03-19 2004-02-12 Cytyc Health Corporation Intraductal management of breast lesions involving therapeutic or diagnostic agents
US20040092894A1 (en) * 1999-03-01 2004-05-13 Cytyc Health Corporation Apparatus, methods and kits for simulaneous delivery of a substance to multiple breast milk ducts
US20040208830A1 (en) * 2003-04-16 2004-10-21 Imtiaz Chaudry Nasal pharmaceutical formulations and methods of using the same
CN1917910A (zh) * 2003-12-23 2007-02-21 Cytyc公司 用于进入乳腺管以执行医疗程序的医疗器械及其方法
US20100112041A1 (en) * 2006-11-21 2010-05-06 Jina Pharmaceuticals, Inc. Endoxifen Compositions And Methods
US20120010245A1 (en) * 2008-12-11 2012-01-12 Besins Healthcare Luxembourg Sarl Transdermal pharmaceutical compositions comprising a serm
US20140088059A1 (en) * 2012-07-13 2014-03-27 South Dakota State University Compositions and Methods for Localized Drug Delivery through Mammary Papillae
CN104203961A (zh) * 2012-03-05 2014-12-10 泽维尔大学 作为用于乳腺癌的治疗的基于硼的4-羟基他莫昔芬和因多昔芬前药
WO2015106094A1 (en) * 2014-01-10 2015-07-16 Atossa Genetics Inc. Transpapillary methods and compositions for diagnosing and treating breast conditions

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6881548B2 (en) * 1997-05-23 2005-04-19 A&G Pharmaceutical, Inc. Methods and kits for diagnosing tumorigenicity and determining resistance to the antineoplastic effects of antiestrogen therapy
US6638727B1 (en) * 1999-01-26 2003-10-28 Cytyc Health Corporation Methods for identifying treating or monitoring asymptomatic patients for risk reduction or therapeutic treatment of breast cancer
US20020117169A1 (en) * 2001-02-27 2002-08-29 Kurz Daniel R. Cover and applicator for a portion of a mammalian body
US20050260277A1 (en) * 2001-02-28 2005-11-24 Giles Brian C Method and formula for anti-tumor and anti-matastatic effect
KR100419298B1 (ko) * 2003-07-28 2004-02-18 조규학 부착형 브래지어 및 그 제조방법
US20050142315A1 (en) * 2003-12-24 2005-06-30 Desimone Joseph M. Liquid perfluoropolymers and medical applications incorporating same
IL177006A0 (en) * 2005-08-02 2006-12-10 Veridex Llc Predicting bone relapse of breast cancer
US20090208944A1 (en) * 2005-12-09 2009-08-20 Goetz Matthew P Assessing outcomes for breast cancer patients treated with tamoxifen
MX2008015372A (es) * 2006-06-02 2009-03-23 Glaxosmithkline Biolog Sa Método para identificar si un paciente sera respondedor o no a inmunoterapia.
BRPI0720724A2 (pt) * 2006-12-27 2014-04-01 Univ Emory Composições e métodos para o tratamento de infecções e tumores
WO2009105640A1 (en) * 2008-02-22 2009-08-27 Virginia Commonwealth University Signatures associated with rejection or recurrence of cancer
WO2010008427A1 (en) * 2008-04-11 2010-01-21 Ludwig Institute For Cancer Research Ltd. Tryptophan catabolism in cancer treatment and diagnosis
US20100069781A1 (en) * 2008-04-15 2010-03-18 Johansen Jerald A Device and method for accessing and treating ducts of mammary glands
US9486431B2 (en) * 2008-07-17 2016-11-08 Micell Technologies, Inc. Drug delivery medical device
WO2011072244A1 (en) * 2009-12-10 2011-06-16 Mount Sinai School Of Medicine Of New York University Method of treatment of breast cancer with tamoxifen
EP2425833A1 (de) * 2010-09-03 2012-03-07 Fresenius Kabi Deutschland GmbH Die intravenöse Applikation von Fischöl/DHA +EPA vor bzw. mit Beginn der Chemotherapie
US20130045179A1 (en) * 2011-08-15 2013-02-21 Mihai Ciustea Combination therapy and methods for treatment and prevention of hyperproliferative diseases
US9517183B2 (en) * 2012-01-30 2016-12-13 Patrick B. Ward Nipple abrasion protector
US20180049999A1 (en) * 2015-04-14 2018-02-22 Atossa Genetics Inc. Compositions and methods of treatment of breast disorders and estrogen-related disorders

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040092894A1 (en) * 1999-03-01 2004-05-13 Cytyc Health Corporation Apparatus, methods and kits for simulaneous delivery of a substance to multiple breast milk ducts
US20040030248A1 (en) * 2002-03-19 2004-02-12 Cytyc Health Corporation Intraductal management of breast lesions involving therapeutic or diagnostic agents
US20040208830A1 (en) * 2003-04-16 2004-10-21 Imtiaz Chaudry Nasal pharmaceutical formulations and methods of using the same
CN1917910A (zh) * 2003-12-23 2007-02-21 Cytyc公司 用于进入乳腺管以执行医疗程序的医疗器械及其方法
US20100112041A1 (en) * 2006-11-21 2010-05-06 Jina Pharmaceuticals, Inc. Endoxifen Compositions And Methods
US20120010245A1 (en) * 2008-12-11 2012-01-12 Besins Healthcare Luxembourg Sarl Transdermal pharmaceutical compositions comprising a serm
CN104203961A (zh) * 2012-03-05 2014-12-10 泽维尔大学 作为用于乳腺癌的治疗的基于硼的4-羟基他莫昔芬和因多昔芬前药
US20140088059A1 (en) * 2012-07-13 2014-03-27 South Dakota State University Compositions and Methods for Localized Drug Delivery through Mammary Papillae
WO2015106094A1 (en) * 2014-01-10 2015-07-16 Atossa Genetics Inc. Transpapillary methods and compositions for diagnosing and treating breast conditions

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KAUSHALKUMAR DAVE ET AL.: "Transpapillary Drug Delivery to the Breast", 《PLOS ONE》 *
LAY MING LEE ET AL.: "In vitro delivery of anti-breast cancer agents directly via the mammary papilla (nipple)", 《INTERNATIONAL JOURNAL OF PHARMACEUTICS》 *
MARTIN C.DYCK ET AL: "The anticancer effects of Vitamin D and omega-3 PUFAs in combination via cod-liver oil: One plus one may equal more than two", 《MED HYPOTHESES》 *

Also Published As

Publication number Publication date
AU2016294526A1 (en) 2018-02-08
CA2992282A1 (en) 2017-01-19
US20180200206A1 (en) 2018-07-19
EP3322406A4 (de) 2019-06-12
WO2017011623A1 (en) 2017-01-19
JP2018520182A (ja) 2018-07-26
EP3322406A1 (de) 2018-05-23

Similar Documents

Publication Publication Date Title
CN108024959A (zh) 用于治疗乳腺病症的经乳头方法和组合物
Šarenac et al. Cervical cancer, different treatments and importance of bile acids as therapeutic agents in this disease
Robertson et al. Inflammatory breast cancer: the disease, the biology, the treatment
Attard et al. Improving the outcome of patients with castration-resistant prostate cancer through rational drug development
Love et al. A feasibility study of the intraductal administration of chemotherapy
Dixon et al. Lessons from the use of aromatase inhibitors in the neoadjuvant setting.
Kota et al. Estradiol as a targeted, late-line therapy in metastatic breast cancer with estrogen receptor amplification
EP3092027A1 (de) Transpapilläre verfahren und zusammensetzungen zur diagnose und behandlung von brusterkrankungen
Lee et al. A randomized Phase I pre-operative window trial of transdermal endoxifen in women planning mastectomy: Evaluation of dermal safety, intra-mammary drug distribution, and biologic effects
Kairemo et al. Lu-177-PSMA treatment for metastatic prostate cancer: Case examples of major responses
Kaur et al. An update on the screening, diagnosis & management of breast cancer: A review with considerations for future fertility
Kolomiets et al. Multidisciplinary approach to treatment of unresectable liver metastases seeded by luminal breast carcinoma
Ward et al. Utilization of iron (III)-doped nanoshells for in vivo marking of nonpalpable tumors using a VX2 rabbit model
Paquette et al. Improved estrogen receptor assessment by PET using the novel radiotracer 4FMFES in ER+ breast cancer patients: an ongoing phase II clinical trial
Kousalya AN UPDATED OVERVIEW ON BREAST CANCER
Iwashita et al. Endoscopic Ultrasound-Guided Fine-Needle Injection of Hydrogen Peroxide into the Pancreas: Feasibility and Tolerability Study Using a Survival Porcine Model
Taghian et al. Inflammatory breast cancer: Clinical features and treatment
Hamada et al. An elderly patient with DCIS of the breast effectively treated with toremifene alone
Mada et al. A Rare Case of Remittent Male Invasive Ductal Carcinoma With New Metastasis After Incomplete Adjuvant Therapy
Kreienberg et al. for the German Cancer Society
Evangelista et al. FDG avidity at PET/CT during adjuvant hormonal therapy in patients with breast cancer
Mayer et al. PART 3 Solid Tumor Malignancies
Fowler et al. Local recurrence of invasive micropapillary breast cancer after mammosite brachytherapy: a case report and literature review
Agarwal et al. CONCEPTS AND EMERGING TRENDS IN MANAGEMENT OF LOCALLY ADVANCED BREAST CANCER
Noriko et al. Solitary fibrous tumor of the head and neck in a child: Case report and review of the literature

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1255302

Country of ref document: HK

CB02 Change of applicant information
CB02 Change of applicant information

Address after: Washington State

Applicant after: Atosa therapeutics

Address before: Washington State

Applicant before: ATOSSA GENETICS, Inc.

WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20180511